Patterns of Breast Cancer Management and Prognosis of Breast Cancer in China
NCT ID: NCT04076111
Last Updated: 2019-09-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
20000 participants
OBSERVATIONAL
2019-09-05
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Multicenter Prospective Observational Cohort Based on a Breast Cancer Medical Record Database in China
NCT06591039
A Nation-wide Multicenter Clinical Epidemiologic Study of Chinese Females With Advanced Breast
NCT03047889
Prognostic Value of Biomarkers in HR + / HER2 - Advanced Breast Cancer
NCT04683770
The Treatment Situation of Chinese County Population With Breast Cancer
NCT05544123
ScreenIng of Genetic Susceptibility Genes for Breast Cancer Patients in CHinese communiTies
NCT04265937
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Agree to enroll in the study and sign the informed consent form
* Histological diagnosis of ductal carcinoma in situ or invasive breast cancer
* Accept the Surgery-based surgical treatment
* Willing to cooperate with follow-up work
Exclusion Criteria
* Previously received neoadjuvant chemotherapy
* Imaging or histological evidence of distant metastasis
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fengxi Su
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fengxi Su
PI
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fengxi Su, MD
Role: STUDY_CHAIR
Sun Yat-sen Menorial Hospital
Qiang liu, MD
Role: STUDY_CHAIR
Sun Yat-sen Menorial Hospital
Musheng Zeng, MD
Role: STUDY_DIRECTOR
Sun Yat-sen University
Qianjun Chen, MD
Role: STUDY_DIRECTOR
Guuangdong Province Hospital of Chinese Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Guangdong Province Hospital of Chinese Medicine
Guangzhou, Guangdong, China
Sun Yat-sen Memorial Hospital,Sun Yat-sen University
Guangzhou, Guangdong, China
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Cancer Hospital OF Shantou University Medical College
Shantou, Guangdong, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BCSCO003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.